Ticker

Whitehawk Therapeutics CEO Dave Lennon outlined the company's strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate (ADC) pipeline built around a shared linker-payload system and focused on targets the company believes can support broad activity across multiple tumor types. Company reset and runway Lennon said the

Whitehawk Therapeutics CEO Dave Lennon presented at TD Cowen's 46th Annual Healthcare Conference, outlining the company's strategy to develop a portfolio of next-generation antibody-drug conjugates (ADCs) and discussing early priorities for its first-in-human studies. Lennon said Whitehawk has advanced two ADC programs into the clinic since launching last year and is working toward initiating a

Profitability This table compares Aadi Bioscience and Nabriva Therapeutics' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Aadi Bioscience -246.06% -71.87% -57.28% Nabriva Therapeutics -148.11% -365.53% -135.81% Institutional and Insider Ownership 52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Aadi Bioscience (NASDAQ: AADI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, valuation, risk, analyst recommendations and earnings. Volatility and Risk Actinium Pharmaceuticals has a

Risk and Volatility Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Valuation and Earnings This table compares Eagle Pharmaceuticals and Aadi Bioscience"s